Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.50 USD
Change Today +0.02 / 1.35%
Volume 562.0
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

prophase labs inc (PRPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/15 - $1.70
52 Week Low
10/8/14 - $1.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PROPHASE LABS INC (PRPH)

Related News

No related news articles were found.

prophase labs inc (PRPH) Related Businessweek News

No Related Businessweek News Found

prophase labs inc (PRPH) Details

ProPhase Labs, Inc. manufactures, markets, and distributes a range of homeopathic and health products in the United States. The company also researches and develops over-the-counter (OTC) drugs, natural base health products with supplements, personal care, and cosmeceutical products. It offers Cold-EEZE, a zinc gluconate lozenge used to reduce the duration of the common cold; and non-lozenge forms of its proprietary zinc gluconate formulation, including Cold-EEZE cold remedy QuickMelts and Cold-EEZE cold remedy oral spray. The company’s Cold-EEZE cold remedy QuickMelts product line consist of Cold-EEZE daytime/nighttime QuickMelts, Cold-EEZE Plus Immune Support + Energy QuickMelts, and Cold-EEZE plus multi-symptom QuickMelts. ProPhase Labs, Inc. also provides organic cough drops and a Vitamin C supplement under the Organix trademark; and contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties, as well as produces private label lozenge products for retail customers. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation and changed its name to ProPhase Labs, Inc. The company was founded in 1989 and is headquartered in Doylestown, Pennsylvania.

54 Employees
Last Reported Date: 03/27/15
Founded in 1989

prophase labs inc (PRPH) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $705.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $435.0K
Compensation as of Fiscal Year 2014.

prophase labs inc (PRPH) Key Developments

ProPhase Labs Receives Non-Compliance Notice From NASDAQ

On May 21, 2015, ProPhase Labs, Inc. received a letter from The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the NASDAQ Global Market. NASDAQ Global Market Listing Rule 5450(b)(1)(A) requires listed companies to maintain a minimum of $10,000,000 in stockholders’ equity. As disclosed by company on May 13, 2015, the Company’s stockholders’ equity as of March 31, 2015 did not meet this requirement. The Company reported that as of March 31, 2015 its stockholders’ equity was $9,370,000. The Notice does not result in the immediate delisting of the Company’s common stock from the NASDAQ Global Market. Rather, in accordance with NASDAQ Listing Rules, the Company has 45 calendar days from the date of the Notice to submit to NASDAQ a plan to regain compliance with this continued listing requirement. If the Company submits a plan, NASDAQ will decide whether to accept such plan, considering criteria such as the likelihood that the plan will result in compliance, the Company’s past compliance history, the reasons for the Company’s current non-compliance, other corporate events that may occur within the review period, the Company’s overall financial condition, and the Company’s public disclosures. If the plan is accepted, NASDAQ may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. If NASDAQ does not accept the Company’s plan, or the Company elects not to submit a plan, the Company may apply to transfer the listing of its common stock to the NASDAQ Capital Market (which has a lower stockholders’ equity requirement for continued listing) if it satisfies all of the criteria for initial listing on the NASDAQ Capital Market. If the Company does not transfer its common stock to the NASDAQ Capital Market, NASDAQ will notify the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a NASDAQ Hearings Panel. The Company presently intends to submit a plan to NASDAQ to regain compliance with the NASDAQ Listing Rules which may include, among other options, seeking additional funding through the issuance of equity securities that would result in dilution of current stockholders’ ownership in the Company. There can be no assurance NASDAQ will accept the Company’s plan.

ProPhase Labs, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ProPhase Labs, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. The company reported net sales were $5.9 million as compared to net sales of $6.2 million last year. The company incurred net loss of $1.4 million or $0.09 per basic and diluted share, compared to net loss of $0.8 million or $0.05 per basic and diluted share last year. The company’s sales are derived principally from its over-the-counter (OTC) cold remedy products. As a consequence, a significant portion of business is highly seasonal, which causes significant variations in operating results from quarter to quarter. Results for the first quarter of 2015 compared to the first quarter of 2014 principally reflect the net effect of (i) a decrease in net sales of $311,000 principally due to the timing of customer purchases and consumer demand as a consequence of the incidence and severity of upper respiratory illnesses, respectively, (ii) an increase of $514,000 in administration costs due principally to an increase in legal and professional costs relating principally to now resolved litigation matters, offset by (iii) a decrease in sales and marketing expenses of $185,000 and (iv) a decrease in research and development expenses of $70,000. Loss from operations was $1.4 million against $0.8 million last year. Loss before income tax was $1.4 million against $0.8 million last year.

ProPhase Labs, Inc. Announces Resignation of Mark Frank from Board

On April 15, 2015, current Board Member Mark Frank notified ProPhase Labs, Inc. of his decision not to seek re-election to the Board. Mr. Frank's retirement from the Board will become effective as of the company's 2015 Annual Meeting of Stockholders on June 16, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRPH:US $1.50 USD +0.02

PRPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $46.16 USD +0.77
Jazz Pharmaceuticals PLC $185.04 USD +0.64
Momenta Pharmaceuticals Inc $21.97 USD -0.03
Pernix Therapeutics Holdings Inc $5.22 USD -0.04
Sagent Pharmaceuticals Inc $25.48 USD +0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation PRPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROPHASE LABS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at